Back

dbGIST: An LLM-Assisted Multi-Omics Resource for Target Exploration and Cross-Dataset Validation in Gastrointestinal Stromal Tumors

Sun, Z.; Zhao, Q.; Li, J.-H.; Li, J.-J.; Liu, H.; Guo, Y.-X.; Tang, Y.-D.; Yang, F.; Liu, X.; Peng, S.-F.; Mi, W.-n.; Zhang, G.; Zhang, Z.; Yuan, M.-L.; Li, G.-H.; Wang, Y.-F.; Liu, C.; Li, S.-L.; Yang, J.-H.; Fu, Y.

2026-05-26 cancer biology
10.64898/2026.05.22.727292 bioRxiv
Show abstract

Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal neoplasms of the gastrointestinal tract, yet GIST-specific omics evidence remains scattered across small cohorts and is not represented as a dedicated disease project in major cancer genomics resources, limiting reproducible target exploration. Here, we present dbGIST (https://www.dbgist.com), a dedicated GIST-focused multi-omics resource built to make dispersed GIST evidence searchable, analyzable, and reusable. dbGIST harmonizes data from 37 centers and 1,991 samples, including pathologically verified in-house cohorts, across genomics, bulk transcriptomics, proteomics, phosphoproteomics, and single-cell transcriptomics, and couples these data with curated clinical annotations covering survival, mutation status, risk stratification, metastasis or recurrence, mitotic index, tumor site and size, and imatinib response. The platform supports cohort-level molecular-clinical association, survival, enrichment, immune-infiltration, drug-sensitivity, and single-cell analyses through interactive visualizations, downloadable source data, and public APIs for programmatic access to reusable analysis outputs and visualization-ready data. An optional LLM-assisted interface helps users navigate analyses and interpret outputs. Using MCM7 as a case study, dbGIST linked a resource-derived candidate to survival, risk features, metastatic or recurrent disease, imatinib-response phenotypes, proliferative cell states, and in vitro GIST-cell behavior. dbGIST therefore provides a traceable and interoperable resource for target exploration and precision oncology research in GIST.

Matching journals

The top 5 journals account for 50% of the predicted probability mass.

1
Genome Medicine
154 papers in training set
Top 0.1%
22.0%
2
Nature Communications
4913 papers in training set
Top 20%
9.9%
3
npj Precision Oncology
48 papers in training set
Top 0.1%
9.9%
4
Nature Cancer
35 papers in training set
Top 0.2%
4.2%
5
Cancer Research
116 papers in training set
Top 0.6%
4.1%
50% of probability mass above
6
JCO Clinical Cancer Informatics
18 papers in training set
Top 0.3%
3.5%
7
Cancer Discovery
61 papers in training set
Top 0.6%
3.5%
8
Cell Reports Medicine
140 papers in training set
Top 2%
3.5%
9
Clinical Cancer Research
58 papers in training set
Top 0.6%
2.7%
10
Nature Medicine
117 papers in training set
Top 1%
2.5%
11
Nucleic Acids Research
1128 papers in training set
Top 10%
1.7%
12
Modern Pathology
21 papers in training set
Top 0.2%
1.7%
13
npj Digital Medicine
97 papers in training set
Top 2%
1.5%
14
Cancer Cell
38 papers in training set
Top 1%
1.3%
15
PLOS Computational Biology
1633 papers in training set
Top 19%
1.3%
16
Nature Genetics
240 papers in training set
Top 6%
0.9%
17
eBioMedicine
130 papers in training set
Top 3%
0.9%
18
Journal of Translational Medicine
46 papers in training set
Top 2%
0.9%
19
Genomics, Proteomics & Bioinformatics
171 papers in training set
Top 5%
0.9%
20
PLOS ONE
4510 papers in training set
Top 64%
0.9%
21
Cell Systems
167 papers in training set
Top 12%
0.8%
22
EMBO Molecular Medicine
85 papers in training set
Top 4%
0.8%
23
Nature
575 papers in training set
Top 16%
0.7%
24
Cancer Medicine
24 papers in training set
Top 1%
0.7%
25
Bioinformatics Advances
184 papers in training set
Top 5%
0.7%
26
Frontiers in Bioinformatics
45 papers in training set
Top 1%
0.6%
27
Experimental & Molecular Medicine
14 papers in training set
Top 0.4%
0.6%
28
Nature Machine Intelligence
61 papers in training set
Top 4%
0.6%
29
Biomedicines
66 papers in training set
Top 4%
0.6%
30
The Journal of Molecular Diagnostics
36 papers in training set
Top 0.6%
0.6%